vTv Therapeutics study finds 54% of T1D adults on automated insulin delivery report hypoglycemia-related burdens

Bitget2026/10/10 12:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

vTv Therapeutics flagged new market research on hypoglycemia burdens in adults with type 1 diabetes using automated insulin delivery systems.
Results were already presented at the Breakthrough T1D Clinical & Research Congress 2026 in Philadelphia.
The analysis found hypoglycemia remains a common, clinically meaningful burden despite wider use of automated insulin delivery technology.
Management framed the findings as supporting demand for add-on therapies such as its oral investigational cadisegliatin alongside insulin.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610100800PRIMZONEFULLFEED9843229) on October 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

vTv Therapeutics study finds 54% of T1D adults on automated insulin delivery report hypoglycemia-related burdens

You may also like

Crypto prices